Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 5,623 out of 355,674 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 152,101 | 163,452 |
| Total Cites | 6,392 | 7,632 |
| H-index | 39 | 40 |
| Hm-index | 8 | 9 |
| Number of Single Authored Papers | 10 | 10 |
| Total Cites to Single Authored Papers | 194 | 201 |
| Number of Single+First Authored Papers | 21 | 21 |
| Total Cites to Single+First Authored Papers | 1,095 | 1,190 |
| Number of Single+First+Last Authored Papers | 26 | 26 |
| Total Cites to Single+First+Last Authored Papers | 1,415 | 1,542 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4,427 | 4,860 |
| Ratio of Total Citations to Distinct Citing Papers | 1.44 | 1.57 |
| Self-Citation Percentage |
16.25%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 5,673 out of 334,837 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 150,684 | 159,489 |
| Total Cites | 5,918 | 7,103 |
| H-index | 38 | 40 |
| Hm-index | 8 | 8 |
| Number of Single Authored Papers | 9 | 9 |
| Total Cites to Single Authored Papers | 186 | 193 |
| Number of Single+First Authored Papers | 20 | 20 |
| Total Cites to Single+First Authored Papers | 1,027 | 1,119 |
| Number of Single+First+Last Authored Papers | 25 | 25 |
| Total Cites to Single+First+Last Authored Papers | 1,344 | 1,467 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4,085 | 4,493 |
| Ratio of Total Citations to Distinct Citing Papers | 1.45 | 1.58 |
| Self-Citation Percentage |
16.68%
|
|
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 5,715 out of 312,644 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 150,402 | 160,203 |
| Total Cites | 5,485 | 6,582 |
| H-index | 37 | 39 |
| Hm-index | 8 | 8 |
| Number of Single Authored Papers | 9 | 9 |
| Total Cites to Single Authored Papers | 177 | 184 |
| Number of Single+First Authored Papers | 20 | 20 |
| Total Cites to Single+First Authored Papers | 952 | 1,039 |
| Number of Single+First+Last Authored Papers | 25 | 25 |
| Total Cites to Single+First+Last Authored Papers | 1,252 | 1,370 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3,790 | 4,170 |
| Ratio of Total Citations to Distinct Citing Papers | 1.45 | 1.58 |
| Self-Citation Percentage |
16.67%
|
|
Asselin, Barbara L.
University of Rochester School of Medicine and Dentistry,
United States
2022 Rank: 149,130
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 5,651 out of 293,195 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 149,130 | 159,245 |
| Total Cites | 4,943 | 5,934 |
| H-index | 35 | 37 |
| Hm-index | 8 | 8 |
| Number of Single Authored Papers | 9 | 9 |
| Total Cites to Single Authored Papers | 162 | 169 |
| Number of Single+First Authored Papers | 19 | 19 |
| Total Cites to Single+First Authored Papers | 878 | 953 |
| Number of Single+First+Last Authored Papers | 24 | 24 |
| Total Cites to Single+First+Last Authored Papers | 1,156 | 1,258 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3,428 | 3,771 |
| Ratio of Total Citations to Distinct Citing Papers | 1.44 | 1.57 |
| Self-Citation Percentage |
16.70%
|
|
Trending Researchers
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.